Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18528956 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL16011495 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL2316716 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL30704932 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL15878722 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL28975489 | 0.97 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL29090597 | 0.86 | KMT2A (0.47) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL17339044 | 0.84 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL415413 | 0.84 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL29203732 | 0.84 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599684-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240156995-A1 | MOLECULAR PROBES AND METHODS OF USE | UNIV CASE WESTERN RESERVE (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3677285-B1 | TARGETING PEPTIDES FOR DETECTING PROSTATE CANCER | UNIV CASE WESTERN RESERVE (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738099-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-20210275695-A1 | MOLECULAR PROBES AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-09 | — | — | US | disclosed |
| EP-3089996-B1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN LA ROCHE (CH) | 2021-07-28 | — | — | EP | disclosed |
| US-20210069338-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN-LA ROCHE INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2010052144-A2 | NEUROPEPTIDE-2-RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| EP-2119455-A1 | Tripartite raftophilic structures and their use | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-1732612-B1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADO TECHNOLOGIES GMBH (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113386-A1 | PEPTIDE CONJUGATES | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-20070231258-A1 | Peptide conjugates | KARYON CTT LTD. (FI) | 2007-10-04 | — | — | US | disclosed |
| EP-1732612-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | Jadolabs Gmbh (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097199-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADOLABS GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156995-A1 | MOLECULAR PROBES AND METHODS OF USE | EDNRB, FGB, FN1 | KMT2A 4637/4885FABP5 142/4885FABP7 84/4885 |
| US-11738099-B2 | Molecular probes and methods of use | DDX21, FUS, DDIT3 | KMT2A 2290/4885FABP5 699/4885FABP7 262/4885 |
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | FGB, CLTB, CD38 | KMT2A 2719/4885FABP5 2394/4885FABP7 2036/4885 |
| US-20210275695-A1 | MOLECULAR PROBES AND METHODS OF USE | EDNRB, FGB, FN1 | KMT2A 4637/4885FABP5 142/4885FABP7 84/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KMT2A 3586/4885FABP5 2777/4885FABP7 3902/4885 |
| US-20070231258-A1 | Peptide conjugates | PTMS, QPCT, CTH | KMT2A 3390/4885FABP5 3207/4885FABP7 3579/4885 |
| US-12599684-B2 | Molecular probes and methods of use | TFRC, FGB, SSTR3 | KMT2A 3714/4885FABP5 741/4885FABP7 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.